Overview:
Breast cancer diagnostic involves various tests that locate the site of beginning and the spread of the tumor to different parts of the body. The disease can be diagnosed at early stages by particular screening tests such as annual mammograms, MRI, and CT scans. When there are visual symptoms of breast cancer, the person is recommended to undergo diagnostic test in order to confirm the disease. Breast cancer diagnostic tests mainly involve biopsy, where a small amount of internal tissue is removed from the body of the patient to observe it under the microscope in order to diagnose the disease. This method can be performed using various diagnostic options such as clinical lab tests, biopsy, and ultrasound techniques available in the breast cancer diagnostic market.
Get a PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/425
Drivers:
Increasing cases of breast cancer is expected to propel growth of the global breast cancer diagnostic market during the forecast period. For instance, in 2015, the National Cancer Institute (NCI) reported that nearly 232, 340 women were diagnosed with breast cancer and out of these, 39,620 cases were fatal. Moreover, according to the data from NCI, 22.9% of the cancer cases in females account for breast cancer, and it accounts for 18.2% of cancer deaths in women.
Furthermore, factors such as increasing geriatric population, growing awareness about regular check-ups for early detection of breast cancer in people, increasing government fund in R&D of breast cancer treatment and diagnostic methods, as well as technological development in medical imaging technologies are also expected to boost growth of the global breast cancer diagnostic market during the forecast period.
Restraints:
Factors such as high cost of diagnostic devices and imaging facilities of breast cancer, and side effects of radiation therapy are expected to hinder growth of the global breast cancer diagnostic market.
Regional Insights:
North America is expected to witness strong growth in the global breast cancer diagnostic market during the forecast period followed by Europe. According to the WHO, breast cancer affects 89.7 per 100,000 people every year in Western Europe.
Furthermore, Asia Pacific is also expected to witness robust growth in the global breast cancer diagnostic market due to increasing number of patients, growing awareness about advantages of early detection of breast cancer, and increasing government investments in healthcare expenditure.
Key Players:
Key players functioning in the global breast cancer diagnostic market are GE Healthcare, Fujifilm Holdings Corporation, Toshiba Corporation, Dilion Technologies Inc., Hologic Inc., Phillips Healthcare, Gamma Medica Inc., and Aurora Imaging Technology Inc.
Request PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/425
Key Development:
In September 2019, Todos medical Ltd., entered into a non-binding Memorandum of Understanding (MOU) with Orot+ to expand their existing launch and distribution partnership for the commercial sale of Todos TM-B1 and TM-B2 breast cancer detection blood tests in Japan.
In July 2019, Exact Sciences Corp entered into a definitive agreement with Genomic Health Inc. to create leading global cancer Diagnostics Company, and to offer two of the strongest and fastest-growing brands in cancer diagnostics, Oncotype DX and Cologuard.
In July 2019, Paragon Biosciences announced the launch of the seventh portfolio company, Qlarity Imaging LLC, founded to harness the value of artificial intelligence (AI) for improving medical outcomes.
Market Taxonomy:
The global breast cancer diagnostic market is divided by diagnostic type, end-user and geography.
By Diagnostic Type:
- Ionizing breast imaging technologies
- Analog Mammography
- 3D breast tomosynthesis
- Full-field digital mammography (FFDM)
- Positron emission tomography/ Computed tomography (PET/CT)
- Positron emission mammography
- Molecular Breast imaging/ breast specific gamma imaging (MBI/BSMI)
- Others
- Non-ionizing imaging technologies:
- Breast Ultrasound
- Breast MRI (Magnetic Resonance Imaging)
- Automated whole breast ultrasound (AWBU)
- Optical Imaging
- Breast thermography
By End User:
- Hospitals
- Diagnostic Clinical laboratories
- Cancer research centers/ institutes
- Ambulatory Surgical centers
By Region:
- North America
- Europe
- Latin America
- Middle East
- Asia Pacific
- Africa
๐๐ฎ๐ฒ ๐๐จ๐ฐ ๐๐ ๐๐ฏ๐๐ข๐ฅ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ ๐ ๐ซ๐จ๐ฆ ๐๐-๐๐% ๐๐ข๐ฅ๐ฅ ๐๐-๐๐๐-๐๐๐๐
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/425
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837